Hims & Hers Health (NYSE:HIMS) Upgraded at Bank of America

Bank of America upgraded shares of Hims & Hers Health (NYSE:HIMS) from an underperform rating to a neutral rating in a report issued on Tuesday morning, Marketbeat reports. Bank of America currently has $23.00 target price on the stock, up from their previous target price of $12.50.

HIMS has been the topic of a number of other reports. Citigroup dropped their price target on Hims & Hers Health from $16.50 to $13.25 and set a “sell” rating on the stock in a research note on Tuesday, February 24th. Leerink Partners reduced their price objective on Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating for the company in a research report on Tuesday, February 24th. Truist Financial reissued a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $30.75.

Hims & Hers Health Stock Down 7.7%

HIMS opened at $23.88 on Tuesday. The stock has a market capitalization of $5.44 billion, a price-to-earnings ratio of 46.81, a PEG ratio of 2.45 and a beta of 2.55. The firm has a 50 day moving average price of $24.01 and a 200-day moving average price of $37.57. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter last year, the company posted $0.11 earnings per share. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. Equities research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has approved a share buyback program on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. The trade was a 53.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 80,463 shares of company stock valued at $2,846,696 in the last ninety days. Corporate insiders own 13.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtus Advisers LLC bought a new stake in Hims & Hers Health during the 2nd quarter worth approximately $26,000. Quent Capital LLC bought a new position in shares of Hims & Hers Health in the third quarter worth approximately $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth approximately $28,000. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health in the third quarter worth $28,000. Finally, Bogart Wealth LLC raised its position in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Large strategic win — the Novo Nordisk alliance replaces risky compounded GLP‑1 sales with branded Wegovy/Ozempic distribution, materially reducing legal exposure and opening recurring revenue from branded weight‑loss drugs; this is a key reason for intraday rallies. Hims & Hers Stock Jumps After Novo Deal
• Positive Sentiment: Wall Street is turning more constructive: Barclays raised its price target to $29 (overweight) and other shops (Needham, Deutsche Bank coverage) have upgraded or issued favorable notes — these ratings helped fuel buyer interest and reduce some uncertainty. Barclays Raises HIMS Target to $29
• Positive Sentiment: Management hires to support the growth phase — Hims & Hers named Kathryn Beiser as Chief Communications Officer to lead external messaging as the company pursues domestic and international expansion, which can help brand & regulatory narrative management. CCO Appointment
• Neutral Sentiment: Speculative activity and intraday momentum — unusually large call option buying and big premarket jumps (reported 7% premarket) indicate elevated investor interest and short‑term positioning; this raises volatility but is not a fundamentals guarantee. Options & Volume Spike
• Negative Sentiment: Regulatory and legal risks remain meaningful — prior FDA scrutiny of compounded GLP‑1s, a Novo Nordisk patent lawsuit and potential DOJ attention continue to weigh on margin visibility and could limit near‑term upside if unresolved. Regulatory & Legal Overhang
• Negative Sentiment: Short-term price pressure and recent drawdown — coverage pieces note a ~29% three‑month decline and intraday moves where HIMS fell more than the broader market; that reflects profit‑taking, headline risk and rotation away from higher‑beta names. Why HIMS Fell More Than Market

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.